Legend Biotech responds to plans to list in Hong Kong: will not comment on market rumors

2026-03-27 01:59:21

Recently, media reports citing sources said that Legend Biotech, a U.S.-listed company, plans to go public in Hong Kong, with an earliest listing expected this year (2026), raising approximately $300 million to $400 million (about HKD 2.34 billion to HKD 3.12 billion). In response, Legend Biotech stated on March 17 that they do not comment on market rumors. (Jiemian News)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes